Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more
Soleno Therapeutics Inc (SLNO) - Net Assets
Latest net assets as of December 2025: $450.12 Million USD
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has net assets worth $450.12 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($563.83 Million) and total liabilities ($113.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $450.12 Million |
| % of Total Assets | 79.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2429.73% |
| 10-Year Change | 13003.03% |
| Growth Volatility | 447.56 |
Soleno Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $450.12 Million | +83.64% |
| 2024-12-31 | $245.11 Million | +55.62% |
| 2023-12-31 | $157.51 Million | +1422.10% |
| 2022-12-31 | $10.35 Million | -41.84% |
| 2021-12-31 | $17.79 Million | -60.93% |
| 2020-12-31 | $45.55 Million | +204.72% |
| 2019-12-31 | $14.95 Million | -50.85% |
| 2018-12-31 | $30.41 Million | +14.62% |
| 2017-12-31 | $26.53 Million | +672.44% |
| 2016-12-31 | $3.44 Million | +6.56% |
| 2015-12-31 | $3.22 Million | +131.20% |
| 2014-12-31 | $-10.33 Million | +72.71% |
| 2013-12-31 | $-37.86 Million | -10.73% |
| 2012-12-31 | $-34.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Soleno Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37797673200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $52.00K | 0.01% |
| Other Comprehensive Income | $415.00K | 0.09% |
| Other Components | $881.02 Million | 195.73% |
| Total Equity | $450.12 Million | 100.00% |
Soleno Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Soleno Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yamada Holdings Co. Ltd
PINK:YMDAF
|
$1.61 Billion |
|
Titan Cement International S.A.
PINK:TTCIF
|
$1.61 Billion |
|
Dialog Group Bhd
KLSE:7277
|
$1.61 Billion |
|
Intershop Holding AG
SW:ISN
|
$1.61 Billion |
|
Werner Enterprises Inc
NASDAQ:WERN
|
$1.61 Billion |
|
Hangzhou Shunwang Tech
SHE:300113
|
$1.61 Billion |
|
Genmab AS
NASDAQ:GMAB
|
$1.61 Billion |
|
NORTH PACIFIC BANK LTD
F:2PT
|
$1.60 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Soleno Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 245,113,000 to 450,115,000, a change of 205,002,000 (83.6%).
- Net income of 20,890,000 contributed positively to equity growth.
- Share repurchases of 100,146,000 reduced equity.
- New share issuances of 215,721,000 increased equity.
- Other comprehensive income increased equity by 54,000.
- Other factors increased equity by 68,483,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $20.89 Million | +4.64% |
| Share Repurchases | $100.15 Million | -22.25% |
| Share Issuances | $215.72 Million | +47.93% |
| Other Comprehensive Income | $54.00K | +0.01% |
| Other Changes | $68.48 Million | +15.21% |
| Total Change | $- | 83.64% |
Book Value vs Market Value Analysis
This analysis compares Soleno Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-1830.50 | $33.62 | x |
| 2013-12-31 | $-2026.90 | $33.62 | x |
| 2014-12-31 | $-610.20 | $33.62 | x |
| 2015-12-31 | $25.65 | $33.62 | x |
| 2016-12-31 | $16.61 | $33.62 | x |
| 2017-12-31 | $44.33 | $33.62 | x |
| 2018-12-31 | $21.75 | $33.62 | x |
| 2019-12-31 | $6.57 | $33.62 | x |
| 2020-12-31 | $10.91 | $33.62 | x |
| 2021-12-31 | $3.35 | $33.62 | x |
| 2022-12-31 | $1.23 | $33.62 | x |
| 2023-12-31 | $9.55 | $33.62 | x |
| 2024-12-31 | $6.10 | $33.62 | x |
| 2025-12-31 | $8.28 | $33.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Soleno Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.97%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.25x
- Recent ROE (4.64%) is above the historical average (-121.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.06 Million |
| 2013 | 0.00% | -123.57% | 1.89x | 0.00x | $79.20K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.84 Million |
| 2015 | -493.47% | -4104.85% | 0.05x | 2.54x | $-16.23 Million |
| 2016 | -351.22% | -831.63% | 0.26x | 1.62x | $-12.41 Million |
| 2017 | -59.04% | 0.00% | -39.80x | 1.47x | $-18.32 Million |
| 2018 | -43.85% | 0.00% | 0.00x | 1.42x | $-16.38 Million |
| 2019 | -205.89% | 0.00% | 0.00x | 2.55x | $-32.27 Million |
| 2020 | -54.10% | 0.00% | 0.00x | 1.43x | $-29.19 Million |
| 2021 | -173.72% | 0.00% | 0.00x | 2.00x | $-32.69 Million |
| 2022 | -232.58% | 0.00% | 0.00x | 2.56x | $-25.10 Million |
| 2023 | -24.75% | 0.00% | 0.00x | 1.15x | $-54.74 Million |
| 2024 | -71.74% | 0.00% | 0.00x | 1.35x | $-200.36 Million |
| 2025 | 4.64% | 10.97% | 0.34x | 1.25x | $-24.12 Million |
Industry Comparison
This section compares Soleno Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Soleno Therapeutics Inc (SLNO) | $450.12 Million | 0.00% | 0.25x | $1.61 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |